Free Trial

Athira Pharma (ATHA) Insider Trading & Ownership

Athira Pharma logo
$0.64 -0.02 (-3.02%)
(As of 11/22/2024 ET)

Athira Pharma (NASDAQ:ATHA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
19.80%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$563,684.04
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$29,592.93
Get ATHA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Athira Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ATHA Insider Buying and Selling by Quarter

Athira Pharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2024Andrew GengosCFOSell1,272$0.57$725.04  
9/5/2024Mark James LittonCEOSell5,032$0.57$2,868.24  
9/5/2024Rachel LeningtonCOOSell2,525$0.57$1,439.25  
6/24/2024Kelly A RomanoDirectorBuy27,400$2.42$66,308.00  
6/21/2024Kelly A RomanoDirectorBuy15,000$2.26$33,900.00  
1/5/2024Andrew GengosInsiderSell1,208$2.91$3,515.28  
1/5/2024Mark James LittonCEOSell4,820$2.91$14,026.20  
1/5/2024Mark WorthingtonGeneral CounselSell2,412$2.91$7,018.92  
12/29/2023Perceptive Advisors LlcDirectorBuy163,954$2.38$390,210.52  
12/27/2023Perceptive Advisors LlcDirectorBuy32,134$2.28$73,265.52  
(Data available from 1/1/2013 forward)

ATHA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Athira Pharma includes Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc, and Rachel Lenington. Learn more on insiders at ATHA.

19.80% of Athira Pharma stock is owned by insiders. Learn more on ATHA's insider holdings.

The following insiders have purchased ATHA shares in the last 24 months: Andrew Gengos ($242,883.84), Glenna Mileson ($142,500.00), James A Johnson ($12,000.00), Kelly A Romano ($198,908.00), and Perceptive Advisors Llc ($463,476.04).

Insiders have purchased a total of 403,500 ATHA shares in the last 24 months for a total of $1,059,767.88 bought.

The following insiders have sold ATHA shares in the last 24 months: Andrew Gengos ($4,240.32), Mark James Litton ($16,894.44), Mark Worthington ($7,018.92), and Rachel Lenington ($1,439.25).

Insiders have sold a total of 17,269 Athira Pharma shares in the last 24 months for a total of $29,592.93 sold.

Athira Pharma Key Executives

  • Dr. Mark J. Litton M.B.A. (Age 56)
    Ph.D., President, CEO & Director
    Compensation: $882.7k
  • Mr. Andrew W. Gengos (Age 60)
    CFO & Chief Business Officer
    Compensation: $396.16k
    1 recent trades
  • Ms. Rachel P. Lenington M.B.A. (Age 51)
    Chief Development Officer & COO
    Compensation: $578k
  • Dr. Kevin Church Ph.D. (Age 39)
    Chief Scientific Officer
    Compensation: $123.67k
  • Ms. Julie Rathbun
    Head of Investor Relations
  • Mr. Mark F. Worthington J.D. (Age 58)
    General Counsel & Corporate Secretary
    Compensation: $503.83k
  • Ms. Samantha Willing
    Chief People Officer
  • Dr. Javier San Martin M.D. (Age 59)
    Chief Medical Officer


This page (NASDAQ:ATHA) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners